|
1
|
Lee RC, Feinbaum RL and Ambros V: The
C. elegans heterochronic gene lin-4 encodes small RNAs with
antisense complementarity to lin-14. Cell. 75:843–854. 1993.
|
|
2
|
Lagos-Quintana M, Rauhut R, Lendeckel W,
et al: Identification of novel genes coding for small expressed
RNAs. Science. 294:853–858. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lee RC and Ambros V: An extensive class of
small RNAs in Caenorhabditis elegans. Science. 294:862–864.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Salaun B, Yamamoto T, Badran B, et al:
Differentiation associated regulation of microRNA expression in
vivo in human CD8+T cell subsets. J Transl Med.
9:442011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ooi AG, Sahoo D, Adorno M, et al:
MicroRNA-125b expands hematopoietic stem cells and enriches for the
lymphoid-balanced and lymphoid-biased subsets. Proc Natl Acad Sci
USA. 107:21505–21510. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ghisi M, Corradin A, Basso K, et al:
Modulation of microRNA expression in human T-cell development:
targeting of NOTCH3 by miR-150. Blood. 117:7053–7062. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Visone R, Veronese A, Balatti V, et al:
MiR-181b: new perspective to evaluate disease progression in
chronic lymphocytic leukemia. Oncotarget. 3:195–202.
2012.PubMed/NCBI
|
|
8
|
Zhu DX, Miao KR, Fang C, et al: Aberrant
microRNA expression in Chinese patients with chronic lymphocytic
leukemia. Leuk Res. 35:730–734. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tavano F, di Mola FF, Piepoli A, et al:
Changes in miR-143 and miR-21 expression and clinicopathological
correlations in pancreatic cancers. Pancreas. 41:1280–1284. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Esquela-Kerscher A and Slack FJ: Oncomirs
- microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006.
View Article : Google Scholar
|
|
11
|
Michael MZ, O’ Connor SM, van Holst
Pellekaan NG, et al: Reduced accumulation of specific microRNAs in
colorectal neoplasia. Mol Cancer Res. 1:882–891. 2003.PubMed/NCBI
|
|
12
|
Lazebnik Y: What are the hallmarks of
cancer? Nat Rev Cancer. 10:232–233. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar
|
|
14
|
Lopez-Camarillo C, Marchat LA,
Arechaga-Ocampo E, et al: MetastamiRs: non-coding microRNAs driving
cancer invasion and metastasis. Int J Mol Sci. 13:1347–1379. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mendell JT and Olson EN: MicroRNAs in
stress signaling and human disease. Cell. 148:1172–1187. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Schetter AJ, Leung SY, Sohn JJ, et al:
MicroRNA expression profiles associated with prognosis and
therapeutic outcome in colon adenocarcinoma. JAMA. 299:425–436.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pallante P, Visone R, Ferracin M, et al:
MicroRNA deregulation in human thyroid papillary carcinomas. Endocr
Relat Cancer. 13:497–508. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhai H and Ju J: Implications of microRNAs
in colorectal cancer development, diagnosis, prognosis, and
therapeutics. Front Genet. 2:000782011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen Y, Gelfond J, McManus LM, et al:
Temporal microRNA expression during in vitro myogenic progenitor
cell proliferation and differentiation: regulation of proliferation
by miR-682. Physiol Genomics. 43:621–630. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu G, Min H, Yue S, et al: Pre-miRNA loop
nucleotides control the distinct activities of mir-181a-1 and
mir-181c in early T cell development. PLoS One. 3:e35922008.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ji J, Yamashita T and Wang XW:
Wnt/beta-catenin signaling activates microRNA-181 expression in
hepatocellular carcinoma. Cell Biosci. 1:42011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ren Y, Gao J, Liu JQ, et al: Differential
signature of fecal microRNAs in patients with pancreatic cancer.
Mol Med Rep. 6:201–209. 2012.PubMed/NCBI
|
|
23
|
Chen L, Yang Q, Kong WQ, et al:
MicroRNA-181b targets cAMP responsive element binding protein 1 in
gastric adenocarcinomas. IUBMB Life. 64:628–635. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Panarelli NC, Chen YT, Zhou XK, et al:
MicroRNA expression aids the preoperative diagnosis of pancreatic
ductal adenocarcinoma. Pancreas. 41:685–690. 2012.PubMed/NCBI
|
|
25
|
Nurul-Syakima AM, Yoke-Kqueen C, Sabariah
AR, et al: Differential microRNA expression and identification of
putative miRNA targets and pathways in head and neck cancers. Int J
Mol Med. 28:327–336. 2011.PubMed/NCBI
|
|
26
|
Ratert N, Meyer HA, Jung M, et al:
Reference miRNAs for miRNAome analysis of urothelial carcinomas.
PLoS One. 7:e393092012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li X, Zhang Y, Zhang H, et al: miRNA-223
promotes gastric cancer invasion and metastasis by targeting tumor
suppressor EPB41L3. Mol Cancer Res. 9:824–833. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Schaefer A, Jung M, Mollenkopf HJ, et al:
Diagnostic and prognostic implications of microRNA profiling in
prostate carcinoma. Int J Cancer. 126:1166–1176. 2010.PubMed/NCBI
|
|
29
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gregory RI and Shiekhattar R: MicroRNA
biogenesis and cancer. Cancer Res. 65:3509–3512. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Eis PS, Tam W, Sun L, et al: Accumulation
of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad
Sci USA. 102:3627–3632. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cervigne NK, Reis PP, Machado J, et al:
Identification of a microRNA signature associated with progression
of leukoplakia to oral carcinoma. Hum Mol Genet. 18:4818–4829.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Frank DA: STAT3 as a central mediator of
neoplastic cellular transformation. Cancer Lett. 251:199–210. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yu H, Kortylewski M and Pardoll D:
Crosstalk between cancer and immune cells: role of STAT3 in the
tumour microenvironment. Nat Rev Immunol. 7:41–51. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yu H, Pardoll D and Jove R: STATs in
cancer inflammation and immunity: a leading role for STAT3. Nat Rev
Cancer. 9:798–809. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
36
|
Iliopoulos D, Jaeger SA, Hirsch HA, et al:
STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are
part of the epigenetic switch linking inflammation to cancer. Mol
Cell. 39:493–506. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sun X, Icli B, Wara AK, et al:
MicroRNA-181b regulates NF-kappaB-mediated vascular inflammation. J
Clin Invest. 122:1973–1990. 2012.PubMed/NCBI
|
|
38
|
Xi Y, Formentini A, Chien M, et al:
Prognostic values of microRNAs in colorectal cancer. Biomark
Insights. 2:113–121. 2006.PubMed/NCBI
|
|
39
|
Nakajima G, Hayashi K, Xi Y, et al:
Non-coding microRNAs hsa-let-7g and hsa-miR-181b are associated
with chemoresponse to S-1 in colon cancer. Cancer Genomics
Proteomics. 3:317–324. 2006.PubMed/NCBI
|
|
40
|
Xu R, Ma N, Wang F, Ma L, et al: Results
of a randomized and controlled clinical trial evaluating the
efficacy and safety of combination therapy with Endostar and S-1
combined with oxaliplatin in advanced gastric cancer. Onco Targets
Ther. 6:925–929. 2013.PubMed/NCBI
|
|
41
|
Watanabe K, Kawahara H, Enomoto H, et al:
Feasibility Study of Oxaliplatin with Oral S-1 or Capecitabine as
First-line Therapy for Patients with Metastases from Colorectal
Cancer. Anticancer Res. 33:4029–4032. 2013.PubMed/NCBI
|
|
42
|
Jiang J, Zheng X, Xu X, et al: Prognostic
significance of miR-181b and miR-21 in gastric cancer patients
treated with S-1/oxaliplatin or doxifluridine/oxaliplatin. PLoS
One. 6:e232712011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhu W, Shan X, Wang T, et al: miR-181b
modulates multidrug resistance by targeting BCL2 in human cancer
cell lines. Int J Cancer. 127:2520–2529. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wang B, Hsu SH, Majumder S, et al:
TGFbeta-mediated upregulation of hepatic miR-181b promotes
hepatocarcinogenesis by targeting TIMP3. Oncogene. 29:1787–1797.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wang B, Li W, Guo K, et al: miR-181b
promotes hepatic stellate cells proliferation by targeting p27 and
is elevated in the serum of cirrhosis patients. Biochem Biophys Res
Commun. 421:4–8. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yan LX, Huang XF, Shao Q, et al: MicroRNA
miR-21 overexpression in human breast cancer is associated with
advanced clinical stage, lymph node metastasis and patient poor
prognosis. RNA. 14:2348–2360. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Mansueto G, Forzati F, Ferraro A, et al:
Identification of a new pathway for tumor progression:
microRNA-181b up-regulation and CBX7 down-regulation by HMGA1
protein. Genes Cancer. 1:210–224. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Jones KB, Salah Z, Del Mare S, et al:
miRNA signatures associate with pathogenesis and progression of
osteosarcoma. Cancer Res. 72:1865–1877. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Xu X, Jia R, Zhou Y, et al:
Microarray-based analysis: Identification of hypoxia-regulated
microRNAs in retinoblastoma cells. Int J Oncol. 38:1385–1393.
2011.PubMed/NCBI
|
|
50
|
Shi L, Cheng Z, Zhang J, et al:
hsa-mir-181a and hsa-mir-181b function as tumor suppressors in
human glioma cells. Brain Res. 1236:185–193. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Ciafre SA, Galardi S, Mangiola A, et al:
Extensive modulation of a set of microRNAs in primary glioblastoma.
Biochem Biophys Res Commun. 334:1351–1358. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Conti A, Aguennouz M, La Torre D, et al:
miR-21 and 221 upregulation and miR-181b downregulation in human
grade II–IV astrocytic tumors. J Neurooncol. 93:325–332.
2009.PubMed/NCBI
|
|
53
|
Zhi F, Chen X, Wang S, et al: The use of
hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators
of astrocytoma. Eur J Cancer. 46:1640–1649. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Slaby O, Lakomy R, Fadrus P, et al:
MicroRNA-181 family predicts response to concomitant
chemoradiotherapy with temozolomide in glioblastoma patients.
Neoplasma. 57:264–269. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Tunca B, Tezcan G, Cecener G, et al:
Olea europaea leaf extract alters microRNA expression in
human glioblastoma cells. J Cancer Res Clin Oncol. 138:1831–1844.
2012. View Article : Google Scholar
|
|
56
|
Calin GA, Dumitru CD, Shimizu M, et al:
Frequent deletions and down-regulation of micro- RNA genes miR15
and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad
Sci USA. 99:15524–15529. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Chen H, Chen Q, Fang M, et al:
MicroRNA-181b targets MLK2 in HL-60 cells. Sci China Life Sci.
53:101–106. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Zhu DX, Zhu W, Fang C, et al: miR-181a/b
significantly enhances drug sensitivity in chronic lymphocytic
leukemia cells via targeting multiple anti-apoptosis genes.
Carcinogenesis. 33:1294–1301. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Zanette DL, Rivadavia F, Molfetta GA, et
al: miRNA expression profiles in chronic lymphocytic and acute
lymphocytic leukemia. Braz J Med Biol Res. 40:1435–1440. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Sivina M, Hartmann E, Vasyutina E, et al:
Stromal cells modulate TCL1 expression, interacting AP-1 components
and TCL1-targeting micro-RNAs in chronic lymphocytic leukemia.
Leukemia. 26:1812–1820. 2012. View Article : Google Scholar : PubMed/NCBI
|
